Results 1 to 10 of about 6,976 (185)

The efficacy of trastuzumab deruxtecan in Chinese breast cancer patients: a real-world multicenter study [PDF]

Frontiers in Oncology
IntroductionIn mainland China, trastuzumab deruxtecan was first authorized in February 2023 as a monotherapy for the treatment of patients with HER-2-positive adult breast cancer who were either unresectable or had metastasized after receiving one or ...
Miao He, Miao He, Xiaohui Liu, Yan Zhang, Zhenyu Shao, Tiantian Sun, Yu Hu   +6 more
doaj   +2 more sources

Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial [PDF]

Nature Medicine, 2023
Fernanda Mosele, Elise Deluche
exaly   +2 more sources

Durable clinical and metabolic response to Trastuzumab Deruxtecan in heavily Pretreated male HER2-low metastatic breast cancer: a case report. [PDF]

Oxf Med Case Reports
Lamsyah O, Belrhali I, Al Harrak Y, Bel Lakhdar M, Lkhoyaali S, Boutayeb S, El Ghissassi I, M'rabti H, Errihani H.   +8 more
europepmc   +2 more sources

Successful Treatment of HER2 V659E Mutation‐Positive Lung Adenocarcinoma With Trastuzumab Deruxtecan: A Case Report [PDF]

Thoracic Cancer
A 67‐year‐old patient with metastatic lung adenocarcinoma harboring a HER2 V659E mutation received trastuzumab deruxtecan (T‐DXd) as second‐line treatment. The V659E mutation is a rare alteration located in the transmembrane domain of HER2. The antitumor
Mariko Nishihara, Yuki Shinno, Yoshihiro Masui, Ken Masuda, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe   +10 more
doaj   +2 more sources

Unexpected Cardiotoxicity in Patients With HER2-Mutant NSCLC Treated With Trastuzumab Deruxtecan: A Case Report

JTO Clinical and Research Reports, 2022
Antibody-drug conjugates targeting receptor tyrosine-protein kinase erbB-2 (ERBB2, HER2) have emerged as promising targeted options for HER2-mutant NSCLC.
Mariona Riudavets, MD, PhD, Arshid Azarine, MD, MSc, Sondes Smaali, MD, Young-Wouk Kim, MD, Vincent Thomas de Montpréville, MD, Alina Miruna Grecea, MD, Charles Naltet, MD, Annas Gazzah, MD, David Planchard, MD, PhD   +8 more
doaj   +1 more source

Pneumonitis as a side effect of breast cancer treatment: T-DXd and/or SBRT?

Liječnički vjesnik, 2023
Breast cancer that overexpresses the human epidermal growth factor receptor 2 (HER2) is considered to be HER2-positive. The novel HER2- directed antibody drug conjugate, trastuzumab deruxtecan (T-DXd), is formed by covalently joining the monoclonal ...
Džana Bjelić, Sara Bognar, Jelena Benčić, Manuela Bajan, Natalija Dedić Plavetić   +4 more
doaj   +1 more source

Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study. [PDF]

Future Oncol
Sakai H, Tsurutani J, Ozaki Y, Ishiguro H, Nozawa K, Yamanaka T, Aogi K, Matsumoto K, Iwasa T, Tokiwa M, Tsuneizumi M, Miyoshi Y, Kitagawa C, Yamamoto M, Takano Y, Imamura CK, Chiba Y, Takiguchi D, Ezumi T, Takano T.   +19 more
europepmc   +3 more sources

Trastuzumab deruxtecan in the treatment of patients with advanced breast cancer with HER2-low expression: Recent studies review

Опухоли женской репродуктивной системы, 2023
The review gives the definition of HER2-low status, shows its clinical and biological role in patients with advanced breast cancer. A unique mechanism of action of trastuzumab deruxtecan and potential for its use in advanced breast cancer with HER2-low ...
I. V. Kolyadina
doaj   +1 more source

Case Report: Trastuzumab deruxtecan in human epidermal growth factor receptor 2-mutated lung cancer with continuous renal replacement therapy. [PDF]

Front Oncol
Wu S, Ke C, Wei M.
europepmc   +3 more sources

Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases

Breast, 2023
Background: Patients with HER2+ breast cancer (BC) frequently develop leptomeningeal metastases (LM). While HER2-targeted therapies have demonstrated efficacy in the neoadjuvant, adjuvant, and metastatic settings, including for parenchymal brain ...
Anna-Maria Lazaratos, Sarah M. Maritan, Andrea Quaiattini, Amelie Darlix, Ivica Ratosa, Emanuela Ferraro, Gaia Griguolo, Valentina Guarneri, Alessia Pellerino, Silvia Hofer, William Jacot, Hans-Joachim Stemmler, Marcel P.H. van den Broek, Nika Dobnikar, Francois Panet, Zubin Lahijanian, Aki Morikawa, Andrew D. Seidman, Riccardo Soffietti, Lawrence Panasci, Kevin Petrecca, April A.N. Rose, Nathaniel Bouganim, Matthew Dankner   +23 more
doaj   +1 more source